The most promising BCL‐2 inhibitor to date is the BH3‐mimetic venetoclax, which has demonstrated efficacy as targeted therapy for t(11;14) in relapsed/refractory myeloma [7]. The gene discussed is BCL2; the disease is plasma cell myeloma.